Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 03 Aug 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 Jun 2023 16:30 CEST |
ULTIMOVACS | Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Jun 2023 15:30 CEST |
ULTIMOVACS | Ultimovacs' Chief Scientific Officer Gustav Gaudernack Receives Norwegian Tech Award's Honorary Prize as an Outstanding Pioneer Against Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Jun 2023 07:00 CEST |
ULTIMOVACS | Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 08 Jun 2023 14:34 CEST |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Jun 2023 12:22 CEST |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 07 Jun 2023 19:08 CEST |
ULTIMOVACS | Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |